Psychedelic Funding Update: Q2 2026
We have updated our Psychedelic Company Financing Tracker to reflect activity in Q2 2026.
Quarterly Fundraising Activity in Psychedelics
Psychedelic financing activity in the second quarter of 2026 broke all records, with just over $1 billion raised over the three-month period across ten events.
The vast majority of that capital came from just one financing, however: LSD drug developer Definium Therapeutics’ whopping $805M round on the back of its positive Phase 3 readout. That’s the largest fundraising event ever in the psychedelics field, by a significant margin.
Elsewhere, 5-MeO-DMT drug developer GH Research netted $117.5M and Helus Pharma (formerly Cybin) closed a $50M raise.
Smaller rounds came from the likes of psychedelics manufacturer Optimi Health, which closed a $15M offering, and drug developer Psilera, which announced a close on $8.8M in seed funding ($2.5M of that seed round was raised back in 2021, the company’s CEO Chris ...
Join Today
Independent data-driven reporting, analysis and commentary on the psychedelics space: from business and drug development through to policy reform and research.
- Regular Bulletins featuring news, analysis, and research
- Articles and deep dives across psychedelic drug development, policy, and research
- Exclusive interviews with researchers, executives, and policymakers
- Bespoke resources and tools including the Psychedelic Bill Tracker
- Quarterly video briefings and slide decks